Compare CRSP & TNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | TNL |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | Switzerland | United States |
| Employees | 393 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.7B |
| IPO Year | 2016 | 2006 |
| Metric | CRSP | TNL |
|---|---|---|
| Price | $51.20 | $74.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 7 |
| Target Price | $70.29 | ★ $84.00 |
| AVG Volume (30 Days) | ★ 1.6M | 566.0K |
| Earning Date | 05-11-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 3.80% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | $289,590,000.00 | ★ $4,021,000,000.00 |
| Revenue This Year | $807.72 | $3.56 |
| Revenue Next Year | $172.52 | $3.55 |
| P/E Ratio | ★ N/A | $60.29 |
| Revenue Growth | ★ 9169.85 | 4.06 |
| 52 Week Low | $44.12 | $55.92 |
| 52 Week High | $78.48 | $81.00 |
| Indicator | CRSP | TNL |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 53.52 |
| Support Level | $47.92 | $70.79 |
| Resistance Level | $59.61 | $78.03 |
| Average True Range (ATR) | 3.39 | 1.88 |
| MACD | -0.83 | -0.54 |
| Stochastic Oscillator | 12.78 | 47.37 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including two vacation exchange brands, Vacation Ownership and Travel and Membership The majority of the revenue is earned from the United States.